Related Experiment Video
Updated: Jun 21, 2025
08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
9.6K
Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications
Tanveer A Tabish1, Mark J Crabtree1,2, Helen E Townley3,4
1Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation (BHF) Centre of Research Excellence, University of Oxford, Oxford, United Kingdom.
JACC. Basic to Translational Science
|July 10, 2024
Summary
Nitric oxide (NO) nanomaterials offer targeted cardiovascular therapies by precisely delivering NO to sites of dysfunction. These advanced materials aim to improve treatment for conditions like atherosclerosis and hypertension with reduced side effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiovascular Medicine
Background:
- Impaired nitric oxide (NO) bioavailability is central to cardiovascular dysfunction, including issues with vasodilation, thrombosis, and inflammation.
- Traditional NO donors lack targeted delivery, necessitating precise NO administration for safe and effective therapeutic levels.
- Nanomaterials offer novel strategies for localized NO generation or release within the body.
Purpose of the Study:
- To review advances in the design and development of NO-releasing nanomaterials for cardiovascular therapeutics.
- To critically examine the therapeutic potential of nanoplatforms in modulating cellular metabolism and vascular tone.
- To assess the ability of NO-releasing nanomaterials to inhibit platelet aggregation and vascular smooth muscle proliferation.
Main Methods:
- Review of recent strategies utilizing polymeric, inorganic (silica, gold) nanoparticles, and nanoscale metal-organic frameworks for NO delivery.
- Discussion of nanomaterials that generate NO endogenously or store and release NO gas.
- Examination of applications in vascular implants like stents and grafts for cardiovascular diseases.
Main Results:
- NO-releasing nanomaterials demonstrate potential for targeted treatment of atherosclerosis, hypertension, and ischemia-reperfusion injury.
- Nanoplatforms can modulate cellular metabolism, regulate vascular tone, and inhibit platelet aggregation.
- These nanomaterials offer a promising approach to limit vascular smooth muscle proliferation with potentially minimal toxic effects.
Conclusions:
- NO-releasing nanomaterials represent a significant advancement in cardiovascular therapeutics.
- Targeted NO delivery via nanoplatforms holds promise for treating a range of cardiovascular diseases.
- Further research into these nanotechnologies could lead to improved patient outcomes and novel treatment strategies.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
01:16Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
01:23Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502